Roche is developing the company’s internal capabilities and building strategic partnerships ready for the next stage in personalized healthcare.

Aubagio, Sanofi

Executives continue to have faith in Sanofi’s strategic plans to get the company to new heights despite continued impact from patent expirations.

The European Medicines Agency’s CHMP adopted a positive opinion for the marketing authorization of Sanofi’s dengue vaccine.

In a move that seems designed to head off potential legislative action, PhRMA announced that member companies would be taking a new approach to DTC television advertising.

The acquisition will combine Revolution Medicines and Warp Drive Bio’s complementary drug discovery technologies and precision oncology programs directed toward frontier oncology targets.

FCB Health Network chief commercial officer Michael Guarino announced the launch of Solve(d), a new offering that enhances the evidence-based planning and execution of clients’ healthcare marketing strategies and tactics.

Ogilvy CommonHealth Worldwide announced that Johanna Skilling, head of planning in the US, was honored as one of the elite 2018 Agency Vanguard Award recipients by DTC Perspectives.

Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, announced the pricing of an initial public offering of 18,000,000 shares of common stock at a price to the public of $18.00 per share.

Cherie Davies joined FCB Chicago as SVP, Group Creative Director.